论文部分内容阅读
目的观察多西他赛治疗晚期非小细胞肺癌的临床疗效及安全性。方法将46例晚期非小细胞肺癌患者随机分为对照组23例和试验组23例。对照组予以第1天静脉滴注多西他赛75 mg·m~(-2)+静脉滴注顺铂80mg·m~(-2),分3 d给药;试验组予以第1天静脉滴注多西他赛75 mg·m-2。2组患者1个周期均为21 d,共化疗3个周期。用酶联免疫吸附实验(ELISA)法检测血清中血管内皮生长因子C(VEGF-C)、血管内皮生长因子受体-2(VEGFR-2)的表达水平。比较2组患者的临床疗效和药物不良反应的发生情况。结果治疗后,试验组和对照组的总疾病控制率均为78.26%(18/23例),差异无统计学意义(P>0.05)。治疗前和治疗后,试验组的VEGF-C分别为(157.97±7.99),(1065.86±51.27)pg·m L~(-1),VEGFR-2分别为(1325.69±58.41),(121.78±10.71)pg·m L~(-1);对照组的VEGF-C分别为(1323.05±65.14),(1057.17±61.12)pg·m L~(-1),VEGFR-2分别为(156.93±9.10),(123.22±12.11)pg·m L~(-1),组内治疗前和治疗后比较差异均有统计学意义(P<0.01),但2组患者治疗后的组间比较,差异均无统计学意义(P>0.05)。试验组发生的药物不良反应有Ⅲ~Ⅳ级白细胞减少,对照组发生的药物不良反应有Ⅲ~Ⅳ级白细胞减少、血小板减少、贫血。试验组和对照组的药物不良反应发生率为4.35%和26.09%,差异有统计学意义(P<0.05)。结论单用多西他赛与多西他赛联合顺铂治疗晚期非小细胞肺癌的临床疗效相似,但前者可明显降低药物不良反应的发生率。
Objective To observe the clinical efficacy and safety of docetaxel in the treatment of advanced non-small cell lung cancer. Methods 46 patients with advanced non-small cell lung cancer were randomly divided into control group 23 cases and test group 23 cases. The control group was given docetaxel 75 mg · m -2 intravenous drip on day 1 and 80 mg · m -2 cisplatin intravenously for 3 days. The experimental group was given intravenous Intravenous injection of docetaxel 75 mg · m-2.2 group of patients were 21 cycles, a total of 3 cycles of chemotherapy. Serum levels of VEGF-C and VEGFR-2 were detected by enzyme linked immunosorbent assay (ELISA). The clinical efficacy and adverse drug reactions in two groups were compared. Results After treatment, the total disease control rates in both experimental and control groups were 78.26% (18/23 cases), with no significant difference (P> 0.05). The levels of VEGF-C in the experimental group were (157.97 ± 7.99), (1065.86 ± 51.27) pg · m L -1 and (1325.69 ± 58.41), (121.78 ± 10.71 ) pg · m L -1. The VEGF-C levels in the control group were (1323.05 ± 65.14), (1057.17 ± 61.12) pg · m L -1 and VEGFR-2 were (156.93 ± 9.10) , (123.22 ± 12.11) pg · m L -1, respectively. There were significant differences between the two groups before and after treatment (P <0.01), but there were no differences between the two groups after treatment Statistical significance (P> 0.05). Adverse drug reactions occurred in the experimental group Ⅲ ~ Ⅳ leukopenia, adverse drug reactions occurred in the control group Ⅲ ~ Ⅳ leukopenia, thrombocytopenia, anemia. The incidences of adverse drug reactions in the experimental and control groups were 4.35% and 26.09%, respectively, with significant differences (P <0.05). Conclusion The clinical efficacy of docetaxel combined with docetaxel plus cisplatin in the treatment of advanced non-small cell lung cancer is similar, but the former can significantly reduce the incidence of adverse drug reactions.